The stock of Pacific Biosciences of California Inc (PACB) has seen a -15.31% decrease in the past week, with a -18.86% drop in the past month, and a -27.54% decrease in the past quarter. The volatility ratio for the week is 7.84%, and the volatility levels for the past 30 days are at 11.26% for PACB. The simple moving average for the past 20 days is -10.38% for PACB’s stock, with a -67.76% simple moving average for the past 200 days.
Is It Worth Investing in Pacific Biosciences of California Inc (NASDAQ: PACB) Right Now?
The stock has a 36-month beta value of 2.03. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PACB is 262.15M, and at present, short sellers hold a 22.87% of that float. On September 03, 2024, the average trading volume of PACB was 8.74M shares.
PACB) stock’s latest price update
The stock of Pacific Biosciences of California Inc (NASDAQ: PACB) has decreased by -1.09 when compared to last closing price of 1.37.Despite this, the company has seen a loss of -15.31% in its stock price over the last five trading days. accesswire.com reported 2024-09-03 that LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. (“PacBio” or “the Company”) (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with Jefferies repeating the rating for PACB by listing it as a “Buy.” The predicted price for PACB in the upcoming period, according to Jefferies is $4 based on the research report published on June 03, 2024 of the current year 2024.
Goldman gave a rating of “Neutral” to PACB, setting the target price at $2.50 in the report published on April 18th of the current year.
PACB Trading at -14.70% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.67% of loss for the given period.
Volatility was left at 11.26%, however, over the last 30 days, the volatility rate increased by 7.84%, as shares sank -11.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.14% lower at present.
During the last 5 trading sessions, PACB fell by -14.69%, which changed the moving average for the period of 200-days by -81.09% in comparison to the 20-day moving average, which settled at $1.5030. In addition, Pacific Biosciences of California Inc saw -86.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Eidel Jeff, who sale 26,760 shares at the price of $1.59 back on Aug 19 ’24. After this action, Eidel Jeff now owns 869,730 shares of Pacific Biosciences of California Inc, valued at $42,602 using the latest closing price.
Van Oene Mark sale 38,011 shares at $1.66 during a trade that took place back on Aug 16 ’24, which means that Van Oene Mark is holding 1,630,815 shares at $63,174 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -1.67 for the present operating margin
- 0.2 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -2.12. The total capital return value is set at -0.22. Equity return is now at value -70.57, with -23.85 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 1.84. The interest coverage ratio of the stock is -22.06.
Currently, EBITDA for the company is -277.67 million with net debt to EBITDA at -3.05. When we switch over and look at the enterprise to sales, we see a ratio of 6.32. The receivables turnover for the company is 5.82for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.01.
Conclusion
To sum up, Pacific Biosciences of California Inc (PACB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
